



Patient and healthcare provider safety in Thai healthcare context: Challenges and future directions



Jiruth Sriratanaban, M.D., Ph.D.

Department of Preventive and Social Medicine,
Faculty of Medicine, Chulalongkorn University

Director, Thailand Research Center for Health Services System

Key issues

- Some international movement
- Some findings from research studies in Thailand
- The Future



WHO Patient Safety Research (2009)

	Developing countries	Countries in transition	Developed countries
	Strong emphasis on applied and evaluative research leading to the development of local cost-effective solutions		
1.	Counterfeit & substandard drugs	Inadequate competencies & skills	Lack of communication & coordination (including coordination across organizations, discontinuity & handovers)
2.	Inadequate competencies & skills	Lack of appropriate knowledge & transfer	Latent organizational failures
3.	Maternal & newborn care	Lack of communication & coordination (including coordination across organizations, discontinuity & handovers)	Poor safety culture & blame-oriented processes
4.	Health care associated infections	Health care associated infections	Inadequate safety indicators
5.	Unsafe injection practices	Maternal and newborn care	Adverse drug events due to drugs & medication errors
6.	Unsafe blood practices	Adverse events due to drugs & medication errors	Care of the frail & elderly

Patient Safety Research Competencies

1. The fundamental concepts of the science of patient safety in their specific social, cultural and economic context.

- 1.1 Basic definitions and foundational concepts, including human factors and organizational theory
- 1.2 The burden of unsafe care
- 1.3 The importance of a culture of safety
- 1.4 The importance of effective communication and collaboration in care delivery teams
- 1.5 The use of evidence-based strategies for improving the quality and safety of care
- 1.6 The identification and management of hazards and risks
- 1.7 The importance of creating environments for safe care
- 1.8 The importance of educating and empowering patients to be partners for safer care

You can't manage if you can't measure.



MATERNITY
AND CHILDREN

Measurement Strategy

Scottish Patient Safety
Programme
Maternity Care
Measurement Package

Code	Measure	Page
Key Measures		
MC01	Rate of stillbirths	6
MC02	Rate of neonatal deaths	7
MC03	Rate of severe post-partum haemorrhages	8
MC04	% of non-medically indicated deliveries prior to 39 weeks gestation	9
MC05	% of women satisfied with the care they received	10
MP01	% of pregnant women offered CO monitoring at booking	11
MP02	% of pregnant women with a CO level ≥ 4 ppm (or who say they are current or recent smokers) that are referred to smoking cessation services	11
MP03	% of pregnant women who continue to smoke who are provided with a tailored package of antenatal care	15
Person-centred Care		
MP04	% of birth plans signed and dated by the woman and midwife	17
Leadership and Culture		
MP05	Number of safety walkrounds	19
MP06	% of actionable items being completed each month	20
MP07	Safety Culture Survey	21
Prevention of Complications and Collaboration		
MP08	% compliance with the daily safety brief bundle	23
MP09	% compliance with surgical briefings	25
MP10	% of exchanges that use a high quality SBAR	26
MP11	% compliance with the significant event debrief bundle	28
MP12	% compliance with team huddles	30
Safe, Effective and Robust Care		
MP13	% compliance with the MEWS bundle	32
MP14	% of observations identified as at risk that have appropriate interventions undertaken in terms of their management as categorised by MEWS	33
MP15	% compliance with the sepsis 6 bundle	34
MP16	% compliance with the PPH prevention bundle	36
MP17	% compliance with the PPH management bundle	38
MP01	% of newborn babies who were normothermic at the point of discharge from labour suite	39
MP18	% of women with a documented discussion regarding fetal movements	40
MP19	% compliance with the stillbirth bundle - TO BE CONFIRMED	41
MP20	% compliance with the VTE prevention bundle	42
Prevention of Infection and Environmental Protection		
MP21	% of staff trained in SBAR	45
MP22	% of relevant staff trained to use CO monitors	46
MP23	Count (and indication) of deliveries occurring at 2.37 to < 29 weeks of gestation completed	47

Patient safety research in Thailand

- A lot of information from quality improvement projects, but limited findings from systematic research.
- Little evidence on safe practices and their outcomes.
- Share a lot, but evidence of LEARNING and IMPROVEMENT ???

Occurrence of adverse events in Thailand

Jama Medical Vol 1 No 1 October 2005, 162-170

Best communication (Original)

Identifying adverse events in hospitalized patients using global trigger tool in Thailand

Saravut Aaronsongkiet¹, Bunk Srinanont², Nattawatthol³, Anant Supasitthakul⁴
¹Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10160, ²The Institute of Hospital Quality Improvement and Accreditation (HQA-Thailand), Jirachulalongkornrajavidyalaya University, Thailand

Subgroup	Number of cases	Percent
Male	371	38.4
Female	335	61.6
<1	108	18.8
1-14	46	8.0
15-29	80	15.5
30-44	107	18.6
45-59	89	15.5
≥60	147	28.2
Acute	326	56.6
Appointment	230	43.4
Obstetric/Gynecology	140	24.3
Surgery	134	26.7
Medicine	113	19.6
Pediatrics	18	2.7
Oncology	21	3.6
Mean (95% CI)	7.7 (6.5-9.0)	
Median (Q1-Q3)	4.0 (2.0-7.0)	




Fig. 1 Number of result in each process of review. E, F, G, H, and I indicate severity-rating

Patient Safety Goals (SIMPLE)		Amount	Percent
S	<i>Safesurgery</i>	48	20.3
S1	<i>Surgical site infection (SSI) prevention</i>	5	2.1
S2	<i>Safe anesthesia</i>	7	3.0
S3	<i>Safe surgical team</i>	9	3.8
S3.1	<i>Correct procedure at correct body site</i>	4	1.7
S3.2	<i>Surgical safety checklist</i>	23	9.7
I	<i>Infection control</i>	40	16.9
I1	<i>Hand hygiene/clean hand</i>	8	3.4
I2	<i>Prevention of healthcare associated infection</i>	14	5.9
I2.1	<i>Catheter-associated urinary tract infection (CAUTI) prevention</i>	8	3.4
I2.2	<i>Ventilator-associated pneumonia (VAP) prevention</i>	6	2.5
I2.3	<i>Central line infection prevention</i>	4	1.7
M	<i>Medication and blood safety</i>	47	17.8
M1	<i>Safe from adverse drug events (ADE)</i>	31	13.1
M1.1	<i>Control of concentrated electrolyte solutions</i>	0	0
M1.2	<i>Improve the safety of high-alert drug</i>	4	1.7
M2	<i>Safe from medication error</i>	1	0.4
M2.1	<i>Look alike sound alike medication names</i>	0	0
M3	<i>Medication reconciliation/assuring medication accuracy at transition in care</i>	0	0
M4	<i>Blood safety</i>	6	2.5
P	<i>Patient care processes</i>	75	31.8
P1	<i>Patients identification</i>	0	0
P2	<i>Communication</i>	0	0
P2.1	<i>Effective communication</i>	0	0
P2.2	<i>Communication during patient care handovers</i>	0	0
P2.3	<i>Communicating critical test results</i>	0	0
P2.4	<i>Verbal or telephone order/communication</i>	0	0
P2.5	<i>Abbreviations, acronyms, symbols and dose designation</i>	0	0
P3	<i>Proper diagnosis</i>	11	4.9
P4	<i>Preventing common complications</i>	53	22.5
P4.1	<i>Preventing pressure ulcers</i>	5	2.1
P4.2	<i>Preventing patient falls</i>	3	1.3
T	<i>Line, tube and catheter</i>	4	1.6
L1	<i>Avoiding catheter and tubing misconnections</i>	1	0.4
F	<i>Emergency response</i>	27	11.4
F1	<i>Response to the deteriorating patient/ Rapid response team (RRT)</i>	3	1.3
F2	<i>Scpais</i>	0	0
E3	<i>Acute coronary syndrome</i>	2	0.8
E4	<i>Maternal and neonatal morbidity</i>	22	9.3

Self efficacy and adverse events

Table 2 Occurrences of adverse events and occurrences of adverse events plus near misses recorded at the end of Months 3, 6, 9 and 12.

	Months 1-3 (n = 310)	Months 4-6 (n = 308)	Months 7-9 (n = 306)	Months 10-12 (n = 299)	Overall incident rate (per 100 man-month)
Adverse events					
Low self-efficacy group (total = 157)	11 (n = 157)	8 (n = 155)	11 (n = 153)	9 (n = 149)	2.12
High self-efficacy group (total = 153)	1 (n = 153)	2 (n = 153)	3 (n = 153)	2 (n = 150)	0.44
Period-by-period unadjusted RR	10.7 [1.5-461.4]	3.9 [0.7-37.9]	3.6 [0.9-20.2]	4.4 [0.9-42.4]	P < 0.001*
Adverse events plus near misses					
Low self-efficacy group (total = 157)	73 (n = 157)	58 (n = 155)	68 (n = 153)	61 (n = 149)	14.11
High self-efficacy group (total = 153)	30 (n = 153)	34 (n = 153)	41 (n = 153)	43 (n = 150)	8.10
Period-by-period unadjusted RR	2.4 [1.5-3.7]	1.7 [1.1-2.6]	1.6 [1.1-2.5]	1.4 [0.9-2.1]	P < 0.001*

*Statistically significant difference in the overall incidence rates between the low- and high self-efficacy groups.

Table 5 Adjusted relative risk of risks of AEs of the LOW self-efficacy group relative to the HIGH self-efficacy group, controlled for significant confounders from bivariate analyses, estimated by Poisson regression using GEE

	Adjusted RR	95% confidence interval	P-value
Self-efficacy: 'low' relative to 'high'	4.7	2.1-10.2	<0.001
Age: '60+' relative to '<60' years old	2.2	0.9-5.1	0.051
SMBG: 'no' relative to '1-3 times per day'	0.8	0.4-1.5	0.60
Use of long-acting insulin: 'Yes' relative to 'No'	3.1	1.7-10.9	0.008
Body mass index: '25+' relative to '< 25'	1.4	0.7-2.7	0.28
Dose insulin: '>50 unit' relative to '<50 unit'	1.2	0.6-2.1	0.51
Status: 'single/window' relative to 'married'	0.7	0.3-1.4	0.35

Note: total number of subjects = 310 (1223 observations).

Findings from HA Evaluation Study (2013-14)

● Hospital experience :

- Improvements could be identified in areas, such as as :
 - ❖ *Risk management system*
 - ❖ *Prevention and control of hospital acquired infection*
 - ❖ *Medication safety*
 - ❖ *Environmental safety (Physical)*
- Effective and context-sensitive measures for monitoring patient safety in hospitals are needed
- Patient safety culture needs continuous strengthening

Surveyors' comments: Opportunities for improvements								
หัวข้อมาตรฐาน (N: ปี'52=14; ปี'53=33; ปี'54=41; ปี'55=72)	จำนวนความเห็นของผู้เยี่ยมสำรวจ							
	ประเด็นขึ้นชม				ประเด็นโอกาสพัฒนา			
	52	53	54	55	52	53	54	55
3. สิ่งแวดล้อมในการดูแลผู้ป่วย (ENV)	7	23	33	61	23	67	20	12
3.1 สิ่งแวดล้อมทางกายภาพและความปลอดภัย (ENV.1)	3	7	12	38	5	24	43	102
3.2 เครื่องมือ/ระบบสารานุกรมโรค(ENV.2)	2	6	9	13	13	22	32	87
3.3 สิ่งแวดล้อมเพื่อการสร้างเสริมสุขภาพและการพิทักษ์สิ่งแวดล้อม (ENV.3)	-	3	4	17	4	22	32	90
4. การป้องกันและควบคุมการติดเชื้อ (IC)	7	14	24	42	24	63	43	76
4.1 การป้องกันและควบคุมการติดเชื้อ (IC)	-	-	2	10	1	-	7	33
4.2 ปฏิบัติการป้องกันการติดเชื้อ (IC.2)	-	-	-	14	2	-	1	36
4.3 การเฝ้าระวัง ติดตามกำกับ และควบคุมการระบาด (IC.3)	-	-	4	3	1	3	14	37
6. ระบบการจัดการด้านยา (MMS)	8	17	33	55	26	75	86	157
6.1 การวางแผน การจัดการ การเก็บและสำรองยา (MMS.1)	-	-	-	6	5	-	7	31
6.2 การใช้ยา (MMS.2)	-	-	-	9	1	2	11	60

Some relevant challenges in the Thai health system

- Aging society and chronic diseases
- Resource limitation and practice variation
- Variety of healthcare providers by ownership, type, levels of competency
- Need for effective and safe facility design and infrastructure
- Work system and job redesign
- Reliance on referral systems
- Patient safety in daily operations
- Consumer empowerment, and patient roles in patient safety
- Legal issues

The Future ...

- Encourage “Management by fact”
- Promote innovation: Work system, Work process, Job design
- Integrate safety culture and work culture
- Apply information technology for patient safety
 - Electronic medical (health) record system
- Rethink hospital and facility design
- Customize patient safety solutions:
“What to do” + “How to make change”
- Engage patients: Health literacy